Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma

Christine H. Chung, Alexis Germain, Rathan M. Subramaniam, Andreas M. Heilmann, Kyle Fedorchak, Siraj M. Ali, Vincent A. Miller, Robert A. Palermo, Carole Fakhry

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Despite recent advances, survival outcomes for those with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) have remained poor. Novel approaches should be investigated to improve outcomes. Methods: A retrospective chart review was performed of a patient who presented with a TNM classification III HNSCC of the oropharynx, positive for human papillomavirus (HPV) who had a complete response to a human epidermal growth factor receptor 2 (HER2)-targeted therapy. Amplification rates of HER2 in the HNSCC Cancer Genome Atlas Network (TCGA) dataset and the FoundationOne genomic profiling dataset were evaluated. Results: Comprehensive genomic profiling of the tumor obtained from the dermal metastasis identified amplification of HER2. Data from TCGA and FoundationOne showed that the frequency of HER2 alteration was not observed to vary significantly with HPV tumor status. Conclusion: This case demonstrates the application of genomic profiling to guide treatments in a patient with HNSCC with advanced metastatic disease refractory to standard of care therapies.

Original languageEnglish (US)
Pages (from-to)E15-E19
JournalHead and Neck
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Squamous Cell Neoplasms
Oropharynx
Atlases
Neoplasm Staging
Standard of Care
Head and Neck Neoplasms
Neoplasms
Therapeutics
Genome
Neoplasm Metastasis
Skin
Survival
human ERBB2 protein
Carcinoma, squamous cell of head and neck
Datasets

Keywords

  • biomarker
  • genomic profiling
  • head and neck squamous cell carcinoma
  • human epidermal growth factor receptor 2 (HER2)
  • trastuzumab

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma. / Chung, Christine H.; Germain, Alexis; Subramaniam, Rathan M.; Heilmann, Andreas M.; Fedorchak, Kyle; Ali, Siraj M.; Miller, Vincent A.; Palermo, Robert A.; Fakhry, Carole.

In: Head and Neck, Vol. 39, No. 1, 01.01.2017, p. E15-E19.

Research output: Contribution to journalArticle

Chung, CH, Germain, A, Subramaniam, RM, Heilmann, AM, Fedorchak, K, Ali, SM, Miller, VA, Palermo, RA & Fakhry, C 2017, 'Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma', Head and Neck, vol. 39, no. 1, pp. E15-E19. https://doi.org/10.1002/hed.24587
Chung, Christine H. ; Germain, Alexis ; Subramaniam, Rathan M. ; Heilmann, Andreas M. ; Fedorchak, Kyle ; Ali, Siraj M. ; Miller, Vincent A. ; Palermo, Robert A. ; Fakhry, Carole. / Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma. In: Head and Neck. 2017 ; Vol. 39, No. 1. pp. E15-E19.
@article{d3973f6325f34ca7818e0fa9d90461e3,
title = "Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma",
abstract = "Background: Despite recent advances, survival outcomes for those with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) have remained poor. Novel approaches should be investigated to improve outcomes. Methods: A retrospective chart review was performed of a patient who presented with a TNM classification III HNSCC of the oropharynx, positive for human papillomavirus (HPV) who had a complete response to a human epidermal growth factor receptor 2 (HER2)-targeted therapy. Amplification rates of HER2 in the HNSCC Cancer Genome Atlas Network (TCGA) dataset and the FoundationOne genomic profiling dataset were evaluated. Results: Comprehensive genomic profiling of the tumor obtained from the dermal metastasis identified amplification of HER2. Data from TCGA and FoundationOne showed that the frequency of HER2 alteration was not observed to vary significantly with HPV tumor status. Conclusion: This case demonstrates the application of genomic profiling to guide treatments in a patient with HNSCC with advanced metastatic disease refractory to standard of care therapies.",
keywords = "biomarker, genomic profiling, head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2), trastuzumab",
author = "Chung, {Christine H.} and Alexis Germain and Subramaniam, {Rathan M.} and Heilmann, {Andreas M.} and Kyle Fedorchak and Ali, {Siraj M.} and Miller, {Vincent A.} and Palermo, {Robert A.} and Carole Fakhry",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/hed.24587",
language = "English (US)",
volume = "39",
pages = "E15--E19",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma

AU - Chung, Christine H.

AU - Germain, Alexis

AU - Subramaniam, Rathan M.

AU - Heilmann, Andreas M.

AU - Fedorchak, Kyle

AU - Ali, Siraj M.

AU - Miller, Vincent A.

AU - Palermo, Robert A.

AU - Fakhry, Carole

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Despite recent advances, survival outcomes for those with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) have remained poor. Novel approaches should be investigated to improve outcomes. Methods: A retrospective chart review was performed of a patient who presented with a TNM classification III HNSCC of the oropharynx, positive for human papillomavirus (HPV) who had a complete response to a human epidermal growth factor receptor 2 (HER2)-targeted therapy. Amplification rates of HER2 in the HNSCC Cancer Genome Atlas Network (TCGA) dataset and the FoundationOne genomic profiling dataset were evaluated. Results: Comprehensive genomic profiling of the tumor obtained from the dermal metastasis identified amplification of HER2. Data from TCGA and FoundationOne showed that the frequency of HER2 alteration was not observed to vary significantly with HPV tumor status. Conclusion: This case demonstrates the application of genomic profiling to guide treatments in a patient with HNSCC with advanced metastatic disease refractory to standard of care therapies.

AB - Background: Despite recent advances, survival outcomes for those with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) have remained poor. Novel approaches should be investigated to improve outcomes. Methods: A retrospective chart review was performed of a patient who presented with a TNM classification III HNSCC of the oropharynx, positive for human papillomavirus (HPV) who had a complete response to a human epidermal growth factor receptor 2 (HER2)-targeted therapy. Amplification rates of HER2 in the HNSCC Cancer Genome Atlas Network (TCGA) dataset and the FoundationOne genomic profiling dataset were evaluated. Results: Comprehensive genomic profiling of the tumor obtained from the dermal metastasis identified amplification of HER2. Data from TCGA and FoundationOne showed that the frequency of HER2 alteration was not observed to vary significantly with HPV tumor status. Conclusion: This case demonstrates the application of genomic profiling to guide treatments in a patient with HNSCC with advanced metastatic disease refractory to standard of care therapies.

KW - biomarker

KW - genomic profiling

KW - head and neck squamous cell carcinoma

KW - human epidermal growth factor receptor 2 (HER2)

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84992488145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992488145&partnerID=8YFLogxK

U2 - 10.1002/hed.24587

DO - 10.1002/hed.24587

M3 - Article

C2 - 27653501

AN - SCOPUS:84992488145

VL - 39

SP - E15-E19

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 1

ER -